{
  "docId": "019de077-691b-72c2-80d2-a28de652ce70",
  "docSlug": "7b833127c4e1241e21c155446b1ba76b",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 42,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines the clinical development strategy for a drug candidate, emphasizing continuity from Phase 2b to Phase 3.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-691b-72c2-80d2-a28de652ce70/15",
  "deckHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70",
  "deckJsonHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70.json",
  "deckAnchorHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.75,
        "x": 0.21,
        "y": 0.35
      },
      "kind": "list",
      "text": "Key design elements largely consistent between Phase 2b and Phase 3 studies; Hamilton Anxiety Scale (HAM-A) primary outcome measure; Limited changes to key inclusion/exclusion criteria; Duration of treatment session monitoring reduced",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fe4d321-1040-4c80-b416-93f0306c04c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.75,
        "x": 0.21,
        "y": 0.15
      },
      "kind": "list",
      "text": "Two Phase 3 pivotal clinical trials in GAD; 12-week randomized, placebo-controlled primary efficacy study design; 40-week extension phase to characterize safety and define retreatment parameters",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54dea5e2-9226-41c1-9e58-2c905eee61cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.75,
        "x": 0.21,
        "y": 0.68
      },
      "kind": "list",
      "text": "Alignment with FDA on program design reached at EOP2 meeting; Study designs believed to be consistent with FDA guidance; Program initiated December 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ace2786-567a-407f-b89e-b933760816ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.17,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Clinical study designs subject to ongoing regulatory discussion... 2. Primary endpoint in Phase 2b study was change from baseline to Week 4... 3. Phase 2b study required 12-hour minimum duration of treatment session monitoring... EOP2: end of Phase 2; GAD: generalized anxiety disorder",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6a80077-04ce-417f-80de-a53e23480bb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "MM120 ODT for GAD | Phase 3 Program Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62e2fa0f-17fd-4b06-b613-5e2fa96470c1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 42,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6a4562d9-e1ba-4048-9ae4-0523b32c6d36",
      "evidence": "The document follows the golden circle framework, starting with the company's vision (why) and presenting its approach (how) and solution (what).",
      "position": 1,
      "objective": "Presenting the company's vision and approach",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}